Eclerx reported impressive deal wins, totalling $51.2 million for Q4 and $140 million for FY25, marking a robust YoY growth of ~54%. Management conveyed strong confidence in the deal pipeline for FY26, noting it is already stronger than what they had entering FY25. Roll-off impact is expected to be stable with no major changes.
NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Dolat Capital Report
Eclerx Ltd.’s constant currency revenue grew 4.2% QoQ (our estimate: 2%) driven by growth in communication, media and technology services and BFSI segments. Operating profit margin declined by 34bps QoQ to 19.8% (our estimate:20.7%) impacted by continued investment and one time charges.
Management is confident in delivering further growth led by strong annual contract value wins of $140 million (up 54% YoY) in FY25 with no major changes in roll offs, implying better growth for FY26. It also reiterated FY26 Ebitda margin guidance of 24%-28%, same as previously guided for FY25.
Eclerx’ investment of ~250 bps in sales/capacity has culminated steady revenue growth (FY25:12.5%) and ACV win momentum (achieved the highest deal wins in Q4 at $51 million), boosting our growth confidence, thereby leading to EPS upgrades of 2.1%/4.0% for FY26/27E.
With growth accelerating we see it poised for re-rating; thus, we revise our rating to ‘Buy’ with target price to Rs 4,200 valuing at 28x FY27E EPS.
Click on the attachment to read the full report:
Also Read: Bharti Airtel Q4 Review: Dolat Capital Maintains 'Add', Hikes Target Price Post Inline Results
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
RECOMMENDED FOR YOU

Emcure Pharmaceuticals Bulk Deal: BC Investments Offloads Stake For Rs 563 Crore


Infosys, Persistent Systems, Mastek, Sonata — Top Stock Picks By HDFC Securities; IT Q1 Results Preview

Emcure Pharma Block Deal: Public Shareholder BC Investments To Sell 2.4% Stake


Eclerx Sees Significant Growth In Cable Media And BFSI Segment
